Better Therapeutics Appoints Dr. Risa Lavizzo-Mourey to its Board of Directors
SAN FRANCISCO, April 20, 2021 — Better Therapeutics, Inc., a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Dr. Risa Lavizzo-Mourey to its board of directors; she will also serve as Compensation Committee chair.
“Dr. Lavizzo-Mourey brings critical insights into health policy, as well as her background as a primary care physician at a critical juncture for Better Therapeutics,” said David Perry, co-founder and chairman of Better Therapeutics. “Her experience and counsel will help us establish our prescription digital therapeutics as the new standard of care for people with cardiometabolic diseases.”
Dr. Lavizzo-Mourey joins the board after previously serving in various high-level roles under three presidential administrations, including as Deputy Administrator for the Agency for Health Care Policy and Research under President George H.W. Bush’s administration, as quality of care chair for President Bill Clinton’s panels on health care, and on President Obama’s Council on Fitness, Sports and Nutrition. Her career combines geriatric medicine and health policy, focusing on disease, disability, prevention, and healthcare issues among minorities. She brings hands-on experience in the fields of research and academia, as a primary care provider, and health policy on a national level with an acute understanding of minority suffering and disenfranchisement.
“I welcome this opportunity to extend my expertise and contribute to the success of Better Therapeutics, which I believe has the potential to truly be transformative in treating cardiometabolic diseases,” said Dr. Lavizzo-Mourey.
Dr. Lavizzo-Mourey currently serves as an independent director and Nominating & Governance Committee member for Intel (NYSE: INTC), an independent director and Compensation & Benefits Committee member for Merck (NYSE: MRK), and as an independent director and Governance & Public Affairs committee member for General Electric (NYSE: GE). Risa is the recipient of numerous awards, including twenty honorary doctorates. She has appeared on Forbes’ list of the most important women in the world eight times, and as one of Modern Healthcare’s one hundred most influential people in health care eleven times.
“Prescription digital therapeutics is a rapid evolving sector of the life science industry, and Better Therapeutics' digitally-delivered cognitive behavioral therapy that addresses the root causes of disease has the potential to become standard practice in cardiometabolic disease treatment,” added Dr. Lavizzo-Mourey.
Boardspan Inc. served as an advisor to Better Therapeutics in this appointment.
